Barclays Raises Estimates on Calumet Specialty Products (CLMT); Royal Purple Acquisition Will Impove Cash Flow
Tweet Send to a FriendGet Alerts CLMT Hot Sheet
Price: $36.24 +1.31%
Rating Summary:
1 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Rating Summary:
1 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Trade CLMT Now!
Barclays maintains an 'Equalweight' on Calumet Specialty Products Partners (NASDAQ: CLMT) price target of $27.00.
Analyst, Richard Gross, said, "Pending specialty products transaction ($335mm Royal Purple acquisition) should be modestly accretive, equity pre-financed. We believe the recently-announced $335mm Royal Purple acquisition enhances CLMT's cash flow stability and provides some upside potential. Though long-term debt is likely to be issued, the partnership's opportunistic equity offering in May mitigates acquisition financing risk as CLMT has sufficient liquidity to complete the acquisition without the need to access the equity capital markets."
FY12 EPS estimate raised from $2.41 to $2.46 and FY13 from $2.14 to $2.30.
For an analyst ratings summary and ratings history on Calumet Specialty Products Partners click here. For more ratings news on Calumet Specialty Products Partners click here.
Shares of Calumet Specialty Products Partners closed at $22.39 yesterday, with a 52 week range of $15.99-$27.74.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Richard Gross, said, "Pending specialty products transaction ($335mm Royal Purple acquisition) should be modestly accretive, equity pre-financed. We believe the recently-announced $335mm Royal Purple acquisition enhances CLMT's cash flow stability and provides some upside potential. Though long-term debt is likely to be issued, the partnership's opportunistic equity offering in May mitigates acquisition financing risk as CLMT has sufficient liquidity to complete the acquisition without the need to access the equity capital markets."
FY12 EPS estimate raised from $2.41 to $2.46 and FY13 from $2.14 to $2.30.
For an analyst ratings summary and ratings history on Calumet Specialty Products Partners click here. For more ratings news on Calumet Specialty Products Partners click here.
Shares of Calumet Specialty Products Partners closed at $22.39 yesterday, with a 52 week range of $15.99-$27.74.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- UPDATE: Raymond James Downgrades Gevo, Inc. (GEVO) to Market Perform
- UPDATE: Bernstein Cuts BlackBerry (BBRY) to Underperform; Notes Weak BB10 Traction
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Mergers and AcquisitionsRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
